Acupoint injection for asthma: Systematic review of randomized controlled trials

Objective: To assess the effectiveness and safety of acupoint injection for the treatment of asthma. Methods: Six electronic databases were searched for randomized controlled trials (RCTs) of acupoint injection for asthma. Two authors extracted data and assessed methodological quality independently using the Cochrane Collaboration Risk of Bias tool. Data were evaluated using RevMan v5.2. Results: Eighteen RCTs involving 1913 participants with asthma were identified. Overall methodological quality of the RCTs was classified as unclear risk of bias. Western medicine (12 RCTs) was injected most frequently into acupoints, followed by Chinese herbal medicine (four RCTs), vitamins (one RCT), and Chinese herbal medicine combined with Western medicine (one RCT). Four RCTs used only one acupoint [ST36 (two RCTs), BL13, CV22], whereas the other RCTs selected multiple acupoints (among which BL13 was used most frequently). One RCT reported mortality, no RCT reported quality of life, 15 RCTs reported the symptom improvement rate, one RCT reported asthma control test (ACT) data, one RCT reported the duration of asthma, three RCTs reported the mean time that asthma was controlled (MTAC), and 13 RCTs reported lung-function tests (LFTs). Some RCTs showed acupoint injection may improve the attack time of asthma, MTAC, and LFTs. Five RCTs reported the outcome of adverse events and showed no significant differences between the acupoint injection group and control group. Conclusions: The findings suggest that acupoint injection may be effective for improving ACT data, duration of asthma, MTAC and LFTs. However, the evidence is insufficient owing to the poor methodological quality of the RCTs